FGF-23 Levels before and after Renal Transplantation by Economidou, Domniki et al.
Hindawi Publishing Corporation
Journal of Transplantation
Volume 2009, Article ID 379082, 5 pages
doi:10.1155/2009/379082
Clinical Study
FGF-23 Levels beforeand after Renal Transplantation
Domniki Economidou, SpyrosDovas,AikateriniPapagianni,
PanagiotisPateinakis,and DimitriosMemmos
University Department of Nephrology, Hippokration General Hospital, 54642 Thessaloniki, Greece
Correspondence should be addressed to Aikaterini Papagianni, aikpapag@otenet.gr
Received 3 February 2009; Accepted 26 April 2009
Recommended by Bruce Kaplan
Phosphatonin ﬁbroblast growth factor-23 (FGF-23) is involved in phosphate (P) excretion and vitamin D metabolism. Recently,
FGF-23 has been suggested to be responsible for the hypophosphatemia and inappropriately low calcitriol levels observed after
renal transplantation. We performed a prospective study to investigate FGF-23 levels in patients with end-stage renal disease
before and after renal transplantation and their probable association with markers of bone and mineral metabolism. Intact
FGF-23 levels were determined before and at 3, 6, and 12 months posttransplantation in 18 renal transplant recipients. Intact
parathyroid hormone (iPTH), calcium (Ca), P, 25(OH)VitD, and 1,25(OH)2VitD levels were measured at the same time periods.
Renalthresholdphosphateconcentration(TmPO4/GFR)wasalsocalculatedat3,6,and12monthsposttransplantation.Theresults
showedthatFGF-23levelsdecreasedby89%3monthsposttransplantation(346 ±146versus37 ±9pg/mL,P<. 01)andremained
stable throughout the study period. iPTH and P levels also decreased signiﬁcantly after renal transplantation, while Ca and
1,25(OH)2VitD increased. Pretransplantation FGF-23 was signiﬁcantly correlated with P levels at 3 months posttransplantation
(P<. 005). In conclusion, FGF-23 levels decrease dramatically after successful renal transplantation. Pre-transplantation FGF-23
correlate with P levels 3 months posttransplantation.
Copyright © 2009 Domniki Economidou et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Phosphatonin ﬁbroblast growth factor-23 (FGF-23) is
involved in phosphate (P) excretion and vitamin D
metabolism. FGF-23 induces phosphaturia and inhibits
renal 1-a hydroxylase leading to decreased calcitriol syn-
thesis [1]. As a result disorders of FGF-23 excess are
characterized by hypophosphatemia with increased renal
phosphate wasting and inappropriately low calcitriol levels
for the degree of hypophosphatemia [2]. Recently, FGF-
23 has been suggested to be responsible for the hypophos-
phatemia and inappropriately low calcitriol levels observed
after renal transplantation [3–6]. Still though, its role in
the hypophosphatemia observed after renal transplantation
remainslargelyunknown.Theaimofthepresentprospective
study was therefore to investigate FGF-23 levels in patients
with end-stage renal disease before and after a successful
renal transplantation and their probable association with
markers of bone and mineral metabolism.
2. Patients andMethods
Eighteen renal transplant recipients (M/F 9/9, mean age 31
± 11 years) consecutively entered the study. Primary diseases
were chronic glomerulonephritis (n = 4), vesicureteral
reﬂux (n = 4), hereditary/cystic kidney disease (n = 3),
tubulointerstitial disease (n = 1), and unknown etiologies
(n = 6). Fifteen patients (83%) received a living related and
three a deceased donor kidney transplants. Sixteen patients
received a ﬁrst transplant and two a second one. Fourteen
patients had been on dialysis before transplantation (median
[interquartile range] dialysis duration 16 [11–42] months)
and four patients had a pre-emptive transplantation. Main-
tenance immunosuppression consisted of corticosteroids
(100%),acalcineurininhibitor(cyclosporinen = 17,94%or
tacrolimus n = 1, 6%) and mycophenolate mofetil (MMF)
(n = 16, 89%) or everolimus (n = 2, 11%). Two doses of
500mg intravenous methylprednisolone were administered
in 11 patients, one on the day before and the other on the2 Journal of Transplantation
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Figure 1: FGF-23 levels before and after successful renal transplan-
tation (Tx: renal transplantation).
day of renal transplantation. In the remaining 7 patients the
same dose was administered once, on the day of renal trans-
plantation. A mean dose of 80 ± 40mg was administered
on the ﬁrst postoperative day. Then methylprednisolone was
gradually tapered to a dose of 4–6mg daily by the end of the
ﬁrst year. Cyclosporine and tacrolimus concentrations were
controlledaccordingtostandardprotocols.MMFdosagewas
adjusted in case of intolerance. The majority of the patients
(n = 14, 78%) received induction therapy with basiliximab.
All rejection episodes (ﬁve in total) were treated successfully
with corticosteroid pulse therapy.
Six patients (33%) had a history of parathyroidectomy
prior to transplantation. Thirteen patients (83%) were
receiving alfacalcidol (One-Alpha, Leo, Princes Risborough,
Buckinghamshire, UK) after transplantation, 6 of them in
combination with alendronate (Fosamax, Merck & Co.,
Inc., USA). Alfacalcidol was administered for osteoporosis
prophylaxis to all patients except those with hypercalcemia
(Serum Ca >10,5mg/dL) and those with 1,25(OH)2VitD
levels greater than 54pg/mL. Six patients (33%) were
receiving calcium salts.
Intact FGF-23 levels were determined by enzyme-linked
immunosorbent assay (ELISA) (Immutopics, San Clemente,
CA, USA) before and 3, 6, and 12 months posttransplan-
tation. The intra- and interassay precision was 4.4% and
6.1% coeﬃcient of variation. Intact parathyroid hormone
(iPTH), calcium (Ca), P, 25(OH)VitD, and 1,25(OH)2VitD
levels were measured at the same time periods. iPTH was
determinedbyIRMA(IMMUNOTECH,Marseilles,France),
and 25(OH)VitD, and 1,25(OH)2VitD were determined by
RIA (BioSource S.A., Brussels, Belgium). Serum creatinine
(Scr), Ca, P, and urine creatinine, and P were measured by
standard techniques using an automated analyzer (Olympus
AV 560, Hamburg, Germany). The renal threshold of P
concentration standardized to glomerular ﬁltration rate
(TmPO4/GFR) was used as a measure of renal P handling
[7]. All patients had satisfactory renal function at month 3
posttransplantation and remained stable until the end of the
study(Scr:1.3±0.2mg/dL).Glomerularﬁltrationrate(GFR)
was estimated using MDRD formula and measured with
51Cr-EDTA between 6 and 12 months posttransplantation
when Scr was stable. Mean eGFR(MDRD) was 62.06 ±
15.76mL/min/1.73m2,a n dm e a n51Cr-EDTA GFR was 50 ±
18 mL/min/1.73m2.
Statistical analysis was performed using SPSS 15.0 for
Windows (SPSS Inc., Chicago, Illinois). Data are expressed
as mean ± SD (parametric parameters) or median with
interquartile range (non-parametric parameters), as appro-
priate. Diﬀerences between study periods in diﬀerent
parameters were analyzed using paired t-test. Compar-
isons between groups were analyzed using unpaired t-test.
Correlations between diﬀerent parameters were analyzed
by Spearman’s rank correlation. Two-sided P<. 05 was
considered statistically signiﬁcant.
3. Results
Compared with FGF-23 levels before transplantation, FGF-
23 levels at the end of 3, 6, and 12 months were signif-
icantly decreased (Figure 1). At the same time periods, P
as well as iPTH levels were also decreased. In addition, a
signiﬁcant increase was noted in Ca and 1,25(OH)2VitD
levels. No signiﬁcant changes were noted in 25(OH)VitD
levels. TmPO4/GFR tended to increase, but the diﬀerence
did not reach statistical signiﬁcance. A statistically signiﬁcant
increaseinTmPO4/GFRwasnotedbetweenmonths1and12
posttransplantation (2.3±0.8v e r s u s3 .3±0.9, P = .04). The
evolution of the aforementioned parameters over the ﬁrst 12
monthsfollowingkidneytransplantationisshowninTable 1.
At 12 months posttransplantation all patients had nor-
mal FGF-23 levels (<50pg/mL). 25(OH)VitD insuﬃciency
(<30ng/mL) was noted in 8 patients (44%) while 3 patients
(17%) had 1,25(OH)2VitD deﬁciency (<20pg/mL). iPTH
levels >65pg/mL were observed in 72% (n = 13) and
17% (n = 3) of the patients at the time of transplantation
and at month 12, respectively. Patients with a history of
parathyroidectomy had lower iPTH levels before transplan-
tation and at month 12 posttransplantation compared to
patients without parathyroidectomy (41 ± 40 versus 236 ±
172, P = .014 and 39 ± 19 versus 74 ± 50pg/mL, P =
.05, resp.). At 12 months posttransplantation, Ca levels
were higher and P levels were lower in patients without
parathyroidectomy (10.0 ± 0.3v e r s u s9 .3 ± 0.4mg/dL,P<
.001 and 3.5 ± 0.6v e r s u s4 .4 ± 0.6mg/dL, P = .007,
resp.). TmPO4/GFR was also lower in patients without
parathyroidectomy (2.8 ± 0.6v e r s u s4 .2 ± 0.9mg/dL,P =
.018) at 12 months posttransplantation. Patients receiving
alfacalcidol tended to have lower iPTH values (48±35 versus
93 ± 63pg/mL, P = .113) at 12 months posttransplantation.
FGF-23 levels also tended to be higher in patients receiving
alfacalcidol (43.4 ± 19.8v e r s u s2 3 .5 ± 5.8pg/mL,P = .08, at
3 months posttransplantation).
A signiﬁcant correlation was observed between
TmPO4/GFR and P levels at 3, 6, and 12 months after
transplantation (P<. 0001, P<. 002, and P<. 0001,
resp.) (Figure 2). In addition, pretransplantation FGF-23
levels were signiﬁcantly correlated with P levels 3 months
posttransplantation (P<. 005). Pretransplantation FGF-23
levels were also correlated with TmPO4/GFR 3 monthsJournal of Transplantation 3
Table 1: Evolution of studied parameters over the ﬁrst 12 months following kidney transplantation.
pre-Tx 3 months 6 months 12 months P§
Phosphate (mg/dL) 5.7 ±1.73 .1 ±0.73 .2 ±0.83 .8 ±0.7 <.005
(2.5–4.5)#
Calcium (mg/dL) 9.2 ±0.99 .8 ±0.59 .9 ±0.69 .9 ±0.6 <.01
(8.8–10.4)#
25(OH)VitD (ng/mL) 37.5 ±23.42 9 .9 ±10.93 4 .1 ±14.23 4 .8 ±15.9N S
(7.6–75)#
1,25(OH)2VitD (pg/mL) 18.5 ±6.73 4 .6 ±14.33 9 .2 ±12.33 4 .7 ±15.4 <.05
(29.6–65.1)#
iPTH (pg/mL) 181 ±171 67 ±41 70 ±40 64 ±45 <.05
(10–65)#
FGF-23 (pg/mL) 346 ±146 37 ±19 32 ±20 31 ±14 <.01
(8.2 –54.3)#$
TmPO4/GFR 2.6 ±0.92 .9 ±1.03 .3 ±0.9N S &
(2.5–4.2)#
ALP (IU/L) 110 ±78 81 ±28 75 ±28 79 ±33 <.05
(30–120)#
Serum creatinine (mg/dL) 7.6 ±3.11 .3 ±0.21 .3 ±0.31 .3 ±0.2 <.001
(0.66–1.1)#
Values are expressed as means ± SD.
§Paired t-test between pre-Tx and post-Tx values.
&Paired t-test between 3 and 12 months post-Tx.
#Normal values.
$Yamashita H et al. European Journal of Endocrinology, 2004.
r = 0.85
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Figure 2: Correlation between TmPO4/GFR and P levels at 3
months postrenal transplantation.
posttransplantation (P = .03). No correlations were
observed between FGF-23 and vitamin D levels before or
after renal transplantation.
Moderate hypophosphatemia (<2.5mg/dL) was
observed relatively infrequently after the ﬁrst month
posttransplantation. Up to 28% of kidney transplant
recipients developed P levels <2.5mg/dL transiently between
1 and 3 months posttransplantation. TmPO4/GFR was
signiﬁcantly lower in these patients (1.9 ± 0.1v e r s u s
2.9 ± 0.8, P = .002). Posttransplantation 1,25(OH)2VitD
levels were higher in hypophosphatemic patients (50.5±10.7
versus 28.8 ± 13.3, P = .007). At month 12, only 1 patient
(6%) still had hypophosphatemia. There was a tendency
toward higher pretransplantation FGF-23 levels in patients
that developed hypophosphatemia (451 ± 177 versus
302 ± 118pg/mL, P = .147). Furthermore, patients that
developed hypophosphatemia tended to have higher pre-
and posttransplantation iPTH levels, but the diﬀerence
did not reach statistical signiﬁcance (280 ± 208 versus
135 ±158pg/mL and 76 ±44 versus 47 ± 41pg/mL, resp.).
Mean iPTH levels decreased by 64% at 3 months
posttransplantation and remained stable thereafter. Pre-
transplantation iPTH correlated signiﬁcantly with Ca and
P levels 12 months posttransplantation (P = .044 and
P = .031, resp.). During the ﬁrst 6 months posttrans-
plantation 3 patients (17%) temporarily developed Ca
levels >10.4mg/dL. At month 12 only 1 patient (6%) had
mild hypercalcemia (Ca levels <12.5mg/dL). Patients with
posttransplantation hypercalcemia tended to have higher
pretransplantation iPTH levels (298 ± 285 versus 151 ±
153pg/mL, P = .205).
4. Discussion
The major ﬁndings of the present study are the following:
(i) intact FGF-23 levels decrease dramatically after successful
renal transplantation and remain within normal limits when
graft function is good, (ii) TmPO4/GFR and P levels at4 Journal of Transplantation
month 3 correlate signiﬁcantly with FGF-23 levels before
transplantation,and(iii)noassociationbetweenFGF-23and
1,25(OH)2VitD levels was found.
In this prospective study, FGF-23 levels were determined
in renal transplant recipients with stable renal function for
a one year period. Intact FGF-23 was measured in order to
avoid measurement of fragments that accumulate in end-
stage renal disease and do not probably reﬂect endogenous
FGF-23 production. In addition, FGF-23 levels before and
after renal transplantation would be more comparable with
the measurement of intact FGF-23 because in patients
with good renal function fragment accumulation is not
observed. We observed a signiﬁcant reduction, already from
the ﬁrst trimester posttransplantation that reached 90% of
pretransplant values. In the following measurements, at 6
and 12 months, there was a small further decline, and
FGF-23 levels were within normal limits in all patients
at month 12 posttransplantation. Phosphate levels and
TmPO4/GFR at month 3 signiﬁcantly correlated with FGF-
23 levels before transplantation. Bones, and in particular
osteoblasts, are considered the possible site of FGF-23
production [8]. In patients with chronic renal failure
and secondary hyperparathyroidism that have undergone
renal transplantation, it is expected that there is a greater
production in the ﬁrst trimester after transplantation,
until osteoblasts become inactive and bone metabolism
is suppressed. It has been reported that corticosteroids,
calcineurin inhibitors, and mTOR inhibitors stimulate FGF-
23 production [9, 10], even though in the ﬁrst months
after transplantation, with the use of higher doses of
these drugs we as well as others observed the greater
reduction [3–6]. Furthermore, hypophosphatemia which
is the major stimulant for FGF-23 secretion is resolved.
Phosphaturia in other solid organ transplantation is not
observed, which points toward its relation either with
secondary hyperparathyroidism or tubular damage. Intact
FGF-23 contributes to the hypophosphatemia observed in
the ﬁrst month after transplantation, but after the ﬁrst
6 months possible causes are persistent secondary hyper-
parathyroidism, tubular damage, and/or immunosuppres-
sive drugs.
Our results are in agreement with those of Pande et al.,
who also observed FGF-23 level reduction as early as the ﬁfth
posttransplantday[5].Intheaforementionedstudy,notonly
FGF-23 was determined but also C-terminal fragments. For
this reason, the excessive and rapid reduction could be due
to increased urinary excretion. In the study by Evenepoel
et al., the results also showed a signiﬁcant reduction of
FGF-23 levels. In this study, there are patients in the ﬁrst
trimester after transplantation with higher than normal
intact FGF-23 levels but with lower glomerular ﬁltration rate
[6].
iPTH concentrations decrease progressively after renal
transplantation. However, resolution of secondary hyper-
parathyroidism (SHPT) is incomplete 1 year after trans-
plantation in about 50% of the recipients [11]. In our
study, mean iPTH levels decreased by 64% at 3 months
posttransplantation and remained low, but at the higher
end of normal by month twelve. A signiﬁcant correlation
was observed between pretransplantation iPTH and Ca
and P levels at 12 months posttransplantation, suggesting
a role for SHPT in the development of postrenal trans-
plantation hypercalcemia and hypophosphatemia. Patients
that developed hypophosphatemia tended to have higher
pre- and posttransplantation iPTH levels as well as higher
pretransplantation FGF-23 levels. These ﬁndings suggest
that FGF-23 and iPTH could act synergistically to cause
phosphaturia, as has been previously suggested [4]. The
role of iPTH in posttransplantation hypophosphatemia is
further supported by the observation that renal transplant
recipients that had undergone parathyroidectomy before
transplantation had lower Ca and higher P levels 12 months
posttransplantation. TmPO4/GFR was also higher in patients
with a history of parathyroidectomy.
Hyposphosphatemia occurs early following renal trans-
plantation and resolves almost completely at 1 year after
transplantation [12]. Temporary mild hyposphosphatemia
was observed in 28% of our patients at 3 months post-
transplantation. In accordance with previous reports, only
1 patient (6%) remained hypophosphatemic at 12 months
posttransplantation. Phosphate levels and TmPO4/GFR were
strongly correlated indicating that low P levels after renal
transplantation are the result of renal phosphate wast-
ing. Pretransplantation but not posttransplantation FGF-
23 levels correlated with P levels as well as TmPO4/GFR
at 3 months posttransplantation. This ﬁnding is consistent
with previous studies that implicate FGF-23 in postrenal
transplantation hyposphosphatemia [3–6].
Up to 91% of our patients had suﬃcient 1,25(OH)2VitD
levels between 3 and 12 months after renal transplan-
tation. No association was found between FGF-23 and
1,25(OH)2VitD levels.
Our study has some advantages. One is that FGF-23
levels were determined with an assay that does not detect C-
terminal fragments. Another is that serial measurements of
FGF-23 after renal transplantation were conducted. Possible
limitations, on the other hand, are the small number of
patients and the use of activated vitamin D analogs and
calcium salts, which may have confounded our results.
In conclusion, FGF-23 levels decrease dramatically after
successful renal transplantation and remain within normal
limits when graft function is good. iPTH and P levels
also decrease signiﬁcantly after renal transplantation, while
Ca and 1,25(OH)2VitD increase. Pretransplantation FGF-
23 levels correlate with TmPO4/GFR and P levels 3 months
posttransplantation. Pretransplantation iPTH also correlate
with Ca and P levels 12 months posttransplantation. No
association was found in this study between FGF-23 and
1,25(OH)2VitD levels. Further studies are needed to eluci-
date the role of FGF-23 in P and 1,25(OH)2VitD metabolism
after renal transplantation.
References
[1] T. Shimada, H. Hasegawa, Y. Yamazaki, et al., “FGF-23 is
a potent regulator of vitamin D metabolism and phosphate
homeostasis,” Journal of Bone and Mineral Research, vol. 19,
no. 3, pp. 429–435, 2004.Journal of Transplantation 5
[2] M. Fukagawa, T. Nii-Kono, and J. J. Kazama, “Role of
ﬁbroblast growth factor 23 in health and in chronic kidney
disease,” CurrentOpinion in Nephrology and Hypertension,vol.
14, no. 4, pp. 325–329, 2005.
[3] I. Bhan, A. Shah, J. Holmes, et al., “Post-transplant hypophos-
phatemia: tertiary ‘Hyper-Phosphatoninism’?” Kidney Inter-
national, vol. 70, no. 8, pp. 1486–1494, 2006.
[ 4 ]P .E v e n e p o e l ,M .N a e s e n s ,K .C l a e s ,D .K u y p e r s ,a n dY .
Vanrenterghem, “Tertiary ‘hyperphosphatoninism’ accentu-
ateshypophosphatemiaandsuppressescalcitriollevelsinrenal
transplant recipients,” American Journal of Transplantation,
vol. 7, no. 5, pp. 1193–1200, 2007.
[5] S. Pande, C. S. Ritter, M. Rothstein, et al., “FGF-23 and sFRP-
4 in chronic kidney disease and post-renal transplantation,”
Nephron Physiology, vol. 104, no. 1, pp. p23–p32, 2006.
[6] P. Evenepoel, M. Bjorn, M. Naesens, et al., “Mineral
metabolism and renal phosphate handling in renal transplant
recipients and patients with chronic kidney disease matched
for eGFR [abstract],” Journal of the American Society of
Nephrology, vol. 18, p. 749A, 2007.
[7] R. J. Walton and O. L. M. Bijvoet, “Nomogram for derivation
of renal threshold phosphate concentration,” The Lancet, vol.
306, no. 7929, pp. 309–310, 1975.
[8] F. Saji, K. Shiizaki, S. Shimada, et al., “Regulation of ﬁbroblast
growth factor 23 production in bone in uremic rats,” Nephron
Physiology, vol. 111, no. 4, pp. 59–66, 2009.
[9] M. Mirams, B. G. Robinson, R. S. Mason, and A. E. Nelson,
“Bone as a source of FGF23: regulation by phosphate?” Bone,
vol. 35, no. 5, pp. 1192–1199, 2004.
[10] D. Krocker, C. Perka, J. Tuischer, et al., “Eﬀects of tacrolimus,
cyclosporin A and sirolimus on MG63 cells,” Transplant
International, vol. 19, no. 7, pp. 563–569, 2006.
[11] A. Torres, V. Lorenzo, and E. Salido, “Calcium metabolism
and skeletal problems after transplantation,” Journal of the
American Society of Nephrology, vol. 13, no. 2, pp. 551–558,
2002.
[12] H. Ghanekar, B. J. Welch, O. W. Moe, and K. Sakhaee, “Post-
renal transplantation hypophosphatemia: a review and novel
insights,” Current Opinion in Nephrology and Hypertension,
vol. 15, no. 2, pp. 97–104, 2006.